Prosecution Insights
Last updated: October 21, 2026
Application No. 18/698,144

AQUEOUS SUSPENSION AGROCHEMICAL COMPOSITION, DISEASE CONTROL METHOD, AND USEFUL PLANT SEEDS

Final Rejection §102§103§DOUBLEPATENT
Filed
Apr 03, 2024
Priority
Oct 29, 2021 — JP 2021 177425 +1 more
Examiner
PACKARD, BENJAMIN J
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Kumiai Chemical Industry Co., Ltd.
OA Round
2 (Final)
67%
Grant Probability
Favorable
3-4
OA Rounds
5m
Est. Remaining
82%
With Interview

Examiner Intelligence

Grants 67% — above average
67%
Career Allowance Rate
905 granted / 1352 resolved
+6.9% vs TC avg
Strong +15% interview lift
Without
With
+15.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
56 currently pending
Career history
1414
Total Applications
across all art units

Statute-Specific Performance

§101
2.1%
-37.9% vs TC avg
§103
48.2%
+8.2% vs TC avg
§102
16.1%
-23.9% vs TC avg
§112
15.8%
-24.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1352 resolved cases

Office Action

§102 §103 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicants' arguments, filed 05/08/2026, have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. Claim Rejections - 35 USC § 102 The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claims 1-3 and 5-12 stand rejected under 35 U.S.C. 102(a)(1) as being anticipated by CN 10840243 A (CN '243). Applicants assert castor oil polyethyenoxy ether is not a vegetable oil derivative within the scope of the claimed invention but is instead functionally labeled a surfactant. Examiner disagrees. While Applicants disclose some potential vegetable derivatives in the instant specification at ¶ 33, the language of the disclosure includes the statement “Examples of the vegetable oil derivative include vegetable oil fatty acid esters…” As such, the disclosure in the specification is not a limiting definition, but instead an open ended list of species which may be within the broader genus. “Though understanding the claim language may be aided by explanations contained in the written description, it is important not to import into a claim limitations that are not part of the claim. For example, a particular embodiment appearing in the written description may not be read into a claim when the claim language is broader than the embodiment.” See MPEP 2111.01(II). Here, even if the cited vegetable oil derivative in CN '243 may be classified as a surfactant, the plain language definition of a vegetable oil derivative still allows the cited vegetable oil derivative in CN '243 to fall within the genus required by the claims. In other words, simply labelling a component a surfactant does not render the same component no longer a vegetable oil derivative. Claim Rejections - 35 USC § 103 Claims 1-12 stand rejected under 35 U.S.C. 103 as being unpatentable over CN 10840243 A (CN '243). Applicants assert the reasons discussed above render this rejection nonobvious. Examiner disagrees for the reasons recited above. Double Patenting Claims 1-12 stand provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over the claims of copending Application No. 18/697,608 (reference application) in view of CN 10840243 A. Applicants assert CN ‘243 does not disclose any embodiments using dichlobetiazox and further fails to teach or suggest a vegetable oil or derivate. Applicants also assert relationship between dichlobetiazox and vegetable oil or vegetable oil derivative in a n aqueous suspension are unexpected in view of the claims of US ‘068. Examiner disagrees. The rejection is based on the combination of references. As such, the skilled artisan would look to ‘608, which claims an agrochemical active and a vegetable oil or vegetable oil derivative, and water, then look to the prior art to find an agrochemical active. CN ‘243 clearly discloses dichlobetiazox as an active which may be used. As such, it remains obvious to use any known active in the composition of ‘068. With regards to the unexpected results, it is unclear what “superior results” are being cited as ¶ 11 of the instant specification simply lists the same components as instant claim 1. Looking to the working embodiments, it appears the comparative examples demonstrate the distinction between the presence of vegetable oils and other additional agents. But the addition of vegetable oil or a vegetable oil derivative is already presumed based on the claims of ‘068, therefore the distinction would need to be the unexpected benefit of the claimed active over other known actives. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BENJAMIN J PACKARD whose telephone number is (571)270-3440. The examiner can normally be reached Mon 2-6pm and Tues-Fri 9:30am-6:30pm + mid-day flex. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana S. Kaup can be reached at (571) 272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BENJAMIN J PACKARD/ Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Apr 03, 2024
Application Filed
Feb 17, 2026
Non-Final Rejection mailed — §102, §103, §DOUBLEPATENT
May 18, 2026
Response Filed
Oct 02, 2026
Final Rejection mailed — §102, §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758517
METHODS FOR TREATMENT OF DAMAGED BILIARY DUCT
4y 3m to grant Granted Oct 13, 2026
Patent 12746227
BENZIMIDAZOLE COMPOUND FOR THE TREATMENT OF METABOLIC DISORDERS
4y 0m to grant Granted Sep 29, 2026
Patent 12746296
IODINE LABELED HYDROGELS AND PRECURSORS THEREOF WITH IMPROVED RADIOPACITY
3y 11m to grant Granted Sep 29, 2026
Patent 12740933
WATER-IN-OIL EMULSION COSMETIC
2y 5m to grant Granted Sep 22, 2026
Patent 12740923
PHARMACEUTICAL FORMULATION
1y 8m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
67%
Grant Probability
82%
With Interview (+15.3%)
2y 11m (~5m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1352 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month